Schematic of blood stem cell mutation accumulation and evolution to cancer.
The Ding Lab was established in 2005. Our mission is to discover genetic alterations relevant to human disease - particularly in cancer - and translate these genomic findings into medically actionable information.
Our research in the field of medical genomics has led to pioneering new software methods that work with state-of-the-art sequencing technology to identify variants that contribute to disease. These events include mutations, gene expression changes, epigenetic modifications, copy number alterations, and structural variations. We often extend such analyses using animal models and high throughput in vitro systems. The resulting information, collected from thousands of tumors across many forms of cancer, allows us to address biological questions that were previously unanswerable regarding the initiation, progression, metastasis, and treatment of cancer at the level of the gene, the pathway, and the cell. Ultimately, this work will contribute to the understanding and treatment of cancer at its most fundamental level.
Our lab is an interdisciplinary team of bioinformatics analysts, research biologists, mathematicians, and computer scientists. We also collaborate extensively with other biomedical researchers and clinicians both at Washington University and elsewhere, on large-scale cancer projects and their associated biological and bioinformatic methodologies.
Cancer Genomics and Proteomics Projects
Computation Methods Projects
The following is a list of software this group has contributed. Many of these are available from the McDonnell Genome Institute's suite of Genome Modeling Tools
For more information on these tools, please visit the Turnkey Variant Analysis Project (TVAP) page.
|1,000 Genomes Project|
|Acute Myeloid Leukemia (AML) Genomics|
|Breast Cancer Genomics|
|Lung Cancer Genomics|
|Mouse Cancer Models|
|Other Cancer Projects|
|Pediatric Cancer Genome Project|
|The Cancer Genome Atlas|
|Turnkey Variant Analysis Project (TVAP)|
|Washington University Cancer Genome Initiative|
Timothy Ley, M.D.
Associate Director, Professor of Medicine